| Vertex Pharmaceuticalsannounced 30 Jan 2020 |
Advance an additional NaV1.8 inhibitor molecule into clinical development for pain due after leader left |
No record found30 Jun 2020 |
| Vertex Pharmaceuticalsannounced 30 Jan 2020 |
Advance an additional NaV1.8 inhibitor molecule into clinical development for pain due after leader left |
No record found30 Jun 2020 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Complete the Phase 1 healthy volunteer study of VX-147 |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Initiate a Phase 2 proof-of-concept study of VX-814 for alpha-1 antitrypsin deficiency |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Provide first clinical data from CTX001 Phase 1/2 studies in sickle cell disease and beta thalassemia |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Initiate a Phase 2 proof-of-concept study of VX-147 for APOL1-mediated kidney disease due after leader left |
Met31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Complete the Phase 1 healthy volunteer study of VX-147 |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Initiate a Phase 2 proof-of-concept study of VX-814 for alpha-1 antitrypsin deficiency |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Provide first clinical data from CTX001 Phase 1/2 studies in sickle cell disease and beta thalassemia |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Oct 2019 |
Initiate a Phase 2 proof-of-concept study of VX-147 for APOL1-mediated kidney disease due after leader left |
Met31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 31 Jul 2019 |
Submit a Marketing Authorization Application in the EU for SYMDEKO |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 31 Jul 2019 |
Submit a Marketing Authorization Application to the European Medicines Agency |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 31 Jul 2019 |
Submit a Marketing Authorization Application in the EU for SYMDEKO |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 31 Jul 2019 |
Submit a Marketing Authorization Application to the European Medicines Agency |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Apr 2019 |
Submit a Marketing Authorization Application in Europe for a triple combination regimen |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 30 Apr 2019 |
Submit a Marketing Authorization Application in Europe for a triple combination regimen |
Met31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Report Phase 3 data for VX-445 triple combination with tezacaftor and ivacaftor |
Met31 Mar 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Report Phase 2b dose-ranging data for oral VX-150 in acute pain |
No record found30 Jun 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Initiate clinical development of first pain molecule from late-stage preclinical work |
No record found31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Advance first FSGS candidate into clinical development |
No record found31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Report Phase 3 data for VX-445 triple combination with tezacaftor and ivacaftor |
Met31 Mar 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Report Phase 2b dose-ranging data for oral VX-150 in acute pain |
No record found30 Jun 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Initiate clinical development of first pain molecule from late-stage preclinical work |
No record found31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 5 Feb 2019 |
Advance first FSGS candidate into clinical development |
No record found31 Dec 2019 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Complete enrollment in the two Phase 3 studies of VX-445 triple combination |
Met31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate clinical development of the first AAT small molecule corrector |
Met31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate the Phase 1/2 sickle cell disease study of CTX001 with CRISPR Therapeutics |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Report data from the VX-445 Phase 3 triple combination studies |
Met31 Mar 2019 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate a Phase 2 study of VX-561 as monotherapy in people with CF |
No record found30 Jun 2019 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Complete enrollment in the two Phase 3 studies of VX-445 triple combination |
Met31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate clinical development of the first AAT small molecule corrector |
Met31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate the Phase 1/2 sickle cell disease study of CTX001 with CRISPR Therapeutics |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Report data from the VX-445 Phase 3 triple combination studies |
Met31 Mar 2019 |
| Vertex Pharmaceuticalsannounced 24 Oct 2018 |
Initiate a Phase 2 study of VX-561 as monotherapy in people with CF |
No record found30 Jun 2019 |
| Vertex Pharmaceuticalsannounced 25 Jul 2018 |
Report Phase 3 data for ivacaftor in infants aged 6 to under 12 months |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 25 Jul 2018 |
Initiate first study of CTX001 in beta thalassemia with partner CRISPR Therapeutics |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 25 Jul 2018 |
Report Phase 3 data for ivacaftor in infants aged 6 to under 12 months |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 25 Jul 2018 |
Initiate first study of CTX001 in beta thalassemia with partner CRISPR Therapeutics |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Submit an IND application for CTX001 in sickle cell disease in the U.S |
Met30 Jun 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Start a Phase 3 study of lumacaftor/ivacaftor in children aged 12 to under 24 months |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Begin clinical trials of CTX001 in Europe for beta-thalassemia |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Submit an IND application for CTX001 in sickle cell disease in the U.S |
Met30 Jun 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Start a Phase 3 study of lumacaftor/ivacaftor in children aged 12 to under 24 months |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 26 Apr 2018 |
Begin clinical trials of CTX001 in Europe for beta-thalassemia |
No record found31 Dec 2018 |
| Vertex Pharmaceuticalsannounced 25 Oct 2017 |
Submit an NDA to the FDA and a MAA line extension to the EMA for ORKAMBI in children aged 2 to 5 |
No record found31 Mar 2018 |
| Vertex Pharmaceuticalsannounced 25 Oct 2017 |
Submit an NDA to the FDA and a MAA line extension to the EMA for ORKAMBI in children aged 2 to 5 |
No record found31 Mar 2018 |
| Vertex Pharmaceuticalsannounced 27 Apr 2017 |
Complete enrollment in a Phase 3 study of tezacaftor/ivacaftor in patients with a gating mutation |
No record found30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 27 Apr 2017 |
Report data from the Phase 1 study of VX-659 in healthy volunteers and people with CF |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 27 Apr 2017 |
Complete enrollment in a Phase 3 study of tezacaftor/ivacaftor in patients with a gating mutation |
No record found30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 27 Apr 2017 |
Report data from the Phase 1 study of VX-659 in healthy volunteers and people with CF |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 29 Mar 2017 |
Submit a Marketing Authorization Application to the EMA for the tezacaftor/ivacaftor combination treatment |
Being checked30 Sep 2017 |
| Vertex Pharmaceuticalsannounced 29 Mar 2017 |
Submit a Marketing Authorization Application to the EMA for the tezacaftor/ivacaftor combination treatment |
Being checked30 Sep 2017 |
| Vertex Pharmaceuticalsannounced 25 Jan 2017 |
Initiate additional Phase 2 proof-of-concept studies of VX-150 in neuropathic and acute pain |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 25 Jan 2017 |
Initiate additional Phase 2 proof-of-concept studies of VX-150 in neuropathic and acute pain |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Start Phase 2 study of next-generation corrector VX-440 in triple combination regimens |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Report Phase 3 efficacy data for ORKAMBI in children ages 6 to 11 in Europe |
Met31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Begin Phase 1 study of next-generation corrector VX-659 |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Report data from two Phase 3 studies of tezacaftor in combination with ivacaftor |
Met30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Advance a fourth next-generation corrector into clinical development |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Start Phase 2 study of next-generation corrector VX-440 in triple combination regimens |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Report Phase 3 efficacy data for ORKAMBI in children ages 6 to 11 in Europe |
Met31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Begin Phase 1 study of next-generation corrector VX-659 |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Report data from two Phase 3 studies of tezacaftor in combination with ivacaftor |
Met30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 25 Oct 2016 |
Advance a fourth next-generation corrector into clinical development |
No record found31 Dec 2017 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Complete enrollment in the 24-week Phase 3 study of VX-661 with ivacaftor |
No record found31 Aug 2016 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Begin Phase 2 development of next-generation correctors with VX-661 and ivacaftor in people with CF |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Report data from the Phase 3 study of VX-661 with ivacaftor in people with two F508del copies |
Met30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Complete enrollment in the 24-week Phase 3 study of VX-661 with ivacaftor |
No record found31 Aug 2016 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Begin Phase 2 development of next-generation correctors with VX-661 and ivacaftor in people with CF |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Jul 2016 |
Report data from the Phase 3 study of VX-661 with ivacaftor in people with two F508del copies |
Met30 Jun 2017 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Complete enrollment in the Phase 3 study of VX-661 with a second mutation causing residual CFTR function |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Complete enrollment in the Phase 2 proof-of-concept study of VX-150 in knee osteoarthritis |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Begin Phase 2 proof-of-concept studies of VX-152 and VX-440 with VX-661 and ivacaftor |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Complete enrollment in the Phase 3 study of VX-661 with a second mutation causing residual CFTR function |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Complete enrollment in the Phase 2 proof-of-concept study of VX-150 in knee osteoarthritis |
No record found31 Dec 2016 |
| Vertex Pharmaceuticalsannounced 27 Apr 2016 |
Begin Phase 2 proof-of-concept studies of VX-152 and VX-440 with VX-661 and ivacaftor |
No record found31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 27 Jan 2016 |
Submit a supplemental New Drug Application for ORKAMBI in children ages 6 to 11 |
Met30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 27 Jan 2016 |
Submit a supplemental New Drug Application for ORKAMBI in children ages 6 to 11 |
Met30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate Phase 2a study of VX-371 in patients taking lumacaftor/ivacaftor |
Met31 Mar 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate a clinical study of KALYDECO in children less than two years of age |
No record found31 Mar 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Submit an sNDA to the FDA for lumacaftor/ivacaftor in children ages 6 to 11 |
Met30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate the first clinical study of VX-970 under NCI sponsorship |
No record found30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete enrollment for the VX-661 and ivacaftor study in people with two copies of F508del mutation |
Late30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate Phase 2 studies of triple combination (VX-440 or VX-152 with VX-661/ivacaftor) |
Met31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete enrollment for VX-661 and ivacaftor studies in gating or residual function mutation patients |
Partly met31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete interim futility analysis of efficacy data from Part A of the VX-661 and ivacaftor study |
Met31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate Phase 2a study of VX-371 in patients taking lumacaftor/ivacaftor |
Met31 Mar 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate a clinical study of KALYDECO in children less than two years of age |
No record found31 Mar 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Submit an sNDA to the FDA for lumacaftor/ivacaftor in children ages 6 to 11 |
Met30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate the first clinical study of VX-970 under NCI sponsorship |
No record found30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete enrollment for the VX-661 and ivacaftor study in people with two copies of F508del mutation |
Late30 Jun 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Initiate Phase 2 studies of triple combination (VX-440 or VX-152 with VX-661/ivacaftor) |
Met31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete enrollment for VX-661 and ivacaftor studies in gating or residual function mutation patients |
Partly met31 Dec 2016 |
| Vertex Pharmaceuticals Inc. / MAannounced 11 Jan 2016 |
Complete interim futility analysis of efficacy data from Part A of the VX-661 and ivacaftor study |
Met31 Dec 2016 |